From 20-30% of patients with advanced basal cell carcinoma (BCC) responded to the PD-1 inhibitor cemiplimab (Libtayo) after resistance or intolerance to a hedgehog-pathway inhibitor, according to updated findings from a phase II trial.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045